S&P 500   4,550.71 (-0.96%)
DOW   36,083.27 (-0.45%)
QQQ   383.14 (-1.74%)
AAPL   188.06 (-1.66%)
MSFT   363.55 (-2.93%)
META   315.13 (-2.98%)
GOOGL   128.12 (-2.84%)
AMZN   142.91 (-2.80%)
TSLA   235.08 (-1.57%)
NVDA   451.33 (-3.49%)
NIO   7.16 (+0.14%)
BABA   73.06 (-1.26%)
AMD   116.69 (-3.87%)
T   16.64 (-0.72%)
F   10.67 (+0.85%)
MU   73.49 (-3.21%)
CGC   0.65 (+4.71%)
GE   121.84 (-0.54%)
DIS   91.64 (-1.02%)
AMC   6.84 (-0.29%)
PFE   29.49 (+2.01%)
PYPL   59.54 (-0.18%)
XOM   102.84 (-0.15%)
S&P 500   4,550.71 (-0.96%)
DOW   36,083.27 (-0.45%)
QQQ   383.14 (-1.74%)
AAPL   188.06 (-1.66%)
MSFT   363.55 (-2.93%)
META   315.13 (-2.98%)
GOOGL   128.12 (-2.84%)
AMZN   142.91 (-2.80%)
TSLA   235.08 (-1.57%)
NVDA   451.33 (-3.49%)
NIO   7.16 (+0.14%)
BABA   73.06 (-1.26%)
AMD   116.69 (-3.87%)
T   16.64 (-0.72%)
F   10.67 (+0.85%)
MU   73.49 (-3.21%)
CGC   0.65 (+4.71%)
GE   121.84 (-0.54%)
DIS   91.64 (-1.02%)
AMC   6.84 (-0.29%)
PFE   29.49 (+2.01%)
PYPL   59.54 (-0.18%)
XOM   102.84 (-0.15%)
S&P 500   4,550.71 (-0.96%)
DOW   36,083.27 (-0.45%)
QQQ   383.14 (-1.74%)
AAPL   188.06 (-1.66%)
MSFT   363.55 (-2.93%)
META   315.13 (-2.98%)
GOOGL   128.12 (-2.84%)
AMZN   142.91 (-2.80%)
TSLA   235.08 (-1.57%)
NVDA   451.33 (-3.49%)
NIO   7.16 (+0.14%)
BABA   73.06 (-1.26%)
AMD   116.69 (-3.87%)
T   16.64 (-0.72%)
F   10.67 (+0.85%)
MU   73.49 (-3.21%)
CGC   0.65 (+4.71%)
GE   121.84 (-0.54%)
DIS   91.64 (-1.02%)
AMC   6.84 (-0.29%)
PFE   29.49 (+2.01%)
PYPL   59.54 (-0.18%)
XOM   102.84 (-0.15%)
S&P 500   4,550.71 (-0.96%)
DOW   36,083.27 (-0.45%)
QQQ   383.14 (-1.74%)
AAPL   188.06 (-1.66%)
MSFT   363.55 (-2.93%)
META   315.13 (-2.98%)
GOOGL   128.12 (-2.84%)
AMZN   142.91 (-2.80%)
TSLA   235.08 (-1.57%)
NVDA   451.33 (-3.49%)
NIO   7.16 (+0.14%)
BABA   73.06 (-1.26%)
AMD   116.69 (-3.87%)
T   16.64 (-0.72%)
F   10.67 (+0.85%)
MU   73.49 (-3.21%)
CGC   0.65 (+4.71%)
GE   121.84 (-0.54%)
DIS   91.64 (-1.02%)
AMC   6.84 (-0.29%)
PFE   29.49 (+2.01%)
PYPL   59.54 (-0.18%)
XOM   102.84 (-0.15%)

AlloVir Stock Price, News & Analysis (NASDAQ:ALVR)

$2.06
+0.09 (+4.57%)
(As of 10:33 AM ET)
Compare
Today's Range
$1.97
$2.12
50-Day Range
$1.34
$2.35
52-Week Range
$1.31
$7.72
Volume
255,821 shs
Average Volume
585,547 shs
Market Capitalization
$234.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75

AlloVir MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
810.2% Upside
$18.75 Price Target
Short Interest
Bearish
10.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$37,132 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.71) to ($1.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

563rd out of 951 stocks

Biological Products, Except Diagnostic Industry

88th out of 159 stocks


ALVR stock logo

About AlloVir Stock (NASDAQ:ALVR)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

ALVR Stock Price History

ALVR Stock News Headlines

Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
AlloVir Inc Ordinary Shares ALVR
AlloVir Inc (ALVR) Reports Q3 2023 Financial Results
AlloVir Reports Third Quarter 2023 Financial Results
AlloVir (NASDAQ: ALVR)
Why AlloVir Stock Dropped Today
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
AlloVir to Present at Upcoming Investor Conferences
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
AlloVir Reports Second Quarter 2023 Financial Results
AlloVir: 'Takes One To Know One'
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why
Why Shares of AlloVir Plummeted This Week
AlloVir Prices Public Offering
Why AlloVir Stock Is Diving Thursday
Why Is AlloVir (ALVR) Stock Down 23% Today?
Pre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE…
See More Headlines
Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALVR
Fax
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.75
High Stock Price Target
$20.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+851.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-168,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.71 per share

Miscellaneous

Free Float
68,473,000
Market Cap
$224.70 million
Optionable
Not Optionable
Beta
1.03
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David L. HallalMr. David L. Hallal (Age 57)
    Executive Chairman of the Board
    Comp: $254.38k
  • Dr. Diana M. Brainard M.D. (Age 52)
    CEO & Director
    Comp: $978.99k
  • Mr. Vikas Sinha C.A. (Age 60)
    CPA, M.B.A., President, CFO & Director
    Comp: $536.21k
  • Mr. Edward Miller J.D. (Age 58)
    General Counsel & Secretary
    Comp: $618.39k
  • Mr. Brett R. HagenMr. Brett R. Hagen (Age 50)
    Chief Accounting Officer
  • Mr. Dana M. Alexander (Age 47)
    Senior Vice President of Technical Operations
  • Dr. Ann M. Leen Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Sonia Choi
    Senior Vice President of Corporate Affairs & Investor Relations
  • Mr. Ugo Capolino Perlingieri
    Head & GM of Europe and Middle East Operations
  • Ms. Cintia Piccina Pharm.D. (Age 50)
    Chief Commercial Officer














ALVR Stock Analysis - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings
or view top-rated stocks.

What is AlloVir's stock price target for 2024?

3 analysts have issued 1 year price targets for AlloVir's stock. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 810.2% from the stock's current price.
View analysts price targets for ALVR
or view top-rated stocks among Wall Street analysts.

How have ALVR shares performed in 2023?

AlloVir's stock was trading at $5.13 on January 1st, 2023. Since then, ALVR shares have decreased by 59.8% and is now trading at $2.06.
View the best growth stocks for 2023 here
.

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our ALVR earnings forecast
.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) announced its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.03.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

When did AlloVir IPO?

(ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.49%), Massachusetts Financial Services Co. MA (0.73%), Wellington Management Group LLP (0.52%), Northern Trust Corp (0.42%), Charles Schwab Investment Management Inc. (0.36%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends
.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALVR) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -